Why the study?
What are the determinants of response to clopidogrel in patients with acute coronary syndrome undergoing PCI?
What are the determinants of response to clopidogrel in patients with acute coronary syndrome undergoing PCI?
The CYP2C19*2 polymorphism is a strong predictor of adverse cardiovascular events and stent thrombosis in patients receiving clopidogrel, highlighting the need for tailored antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
May support alternative P2Y12 inhibitors in known CYP2C19*2 carriers; leaves open whether genotyping improves outcomes in ACS-PCI.
Betti Giusti (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: